Lomustine

What it is used for

Gleostine is an alkylating drug indicated for the treatment of patients with: Brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures. Hodgkin's lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy. Brain Tumors Gleostine is indicated for the treatment of patients with primary and metastatic brain tumors following appropriate surgical and/or radiotherapeutic procedures.

Hodgkin's Lymphoma Gleostine is indicated as a component of combination chemotherapy for the treatment of patients with Hodgkin's lymphoma whose disease has progressed following initial chemotherapy.

Side effects, and when to stop

The following serious adverse reactions are discussed in greater detail in other sections of the labeling:

• Delayed myelosuppression
• Risks of overdosage
• Pulmonary toxicity
• Secondary malignancies
• Hepatotoxicity
• Nephrotoxicity

The following adverse reactions associated with the use of Gleostine were identified in clinical trials or postmarketing reports. Because these reactions were reported from a population of uncertain size, it is not possible to estimate their frequency, reliability, or establish a causal relationship to drug exposure.

Gastrointestinal disorders: nausea, vomiting, and stomatitis

Ocular disorders: optic atrophy, visual disturbances, and blindness

Neurologic disorders: disorientation, lethargy, ataxia, and dysarthria

Other: alopecia

Who should not take it

None.

Storing it

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Avoid temperatures over 40°C (104°F).

Gleostine is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1

To minimize the risk of dermal exposure, always wear impervious gloves when handling bottles containing Gleostine capsules. Do not break Gleostine capsules; avoid exposure to broken capsules. If dermal contact occurs, wash areas of skin contact immediately and thoroughly.